SeaStar Medical ($ICU): Will Hospital Adoption Support Growth?

01 Scenarios: hospital adoption, adult evidence and the funding bridge

Bull case

If hospitals turn the new procedure codes into easier ordering and repeat use of QUELIMMUNE, SeaStar could grow its pediatric business while making the adult development programme more credible to funders. The codes became effective on October 1, 2026, and the company reported 20 hospital customers with its August 12 update. A constructive outcome would require rising sales, continued reassuring safety evidence and enough capital to finish NEUTRALIZE-AKI without financing that overwhelms the benefit for existing shareholders. Coding alone would not establish any of these outcomes. Source Source

The adult programme could provide the larger change in the investment case if recruitment reaches the company’s target around year-end 2026 or in the first quarter of 2027, followed by a positive result and a credible regulatory submission. In the August 12 announcement, SeaStar had enrolled 223 of a planned 339 patients and targeted a PMA application near the end of 2027, conditional on a successful trial. The constructive case would therefore be a sequence of funded milestones, not an assumption that pediatric commercialization already validates an adult approval. Source

The August release also says the company is working with the FDA on a modular PMA, a format in which sections of the application are submitted and reviewed as they are completed. That can spread the regulatory work over time, but it does not change the condition that the decisive clinical module must contain a positive NEUTRALIZE-AKI result. Source

Base case

If pediatric sales continue to grow but remain small relative to clinical expenditure, SeaStar would remain dependent on external financing during the adult trial. The June 30 accounts show $6.959 million in cash, $1.110 million in first-half revenue and $5.755 million of operating cash use over the same six months. This supports a business with a real commercial product, but not one whose sales fund its development ambitions. The base case would be incremental adoption accompanied by further share issuance and uncertainty over the timing of the adult milestone. Source

The October 6 conference appearance and the October 22 ASN poster could help clinicians understand the device without delivering new pivotal results; the poster concerns pediatric registry patients, not the adult trial. Under this scenario, the meaningful updates would be new hospital use, the pace of enrollment, the next cash balance and the terms of capital raised. A presentation, a billing code or an additional hospital would each be progress in its own category; none would substitute for the combination of clinical success and adequate financing. Source Source Source

Bear case

If recruitment takes longer, pediatric orders disappoint or equity financing becomes harder to execute, the cash constraint could become more important than the product opportunity. The August 12 financial report explicitly raises substantial doubt about the company’s ability to continue as a going concern. It also says the ATM was restricted by baby-shelf limitations at June 30. Access to a standby equity facility would not remove the need for favorable market conditions or the dilution created by issuing shares. Source

A negative adult result, an emerging safety concern or unfavorable financing terms would weaken this reading further. The September FDA pediatric review was reassuring within its defined scope, but it was not an adult efficacy decision. Shareholders could face dilution even while the underlying clinical work progresses, particularly if capital has to be raised before the most valuable evidence arrives. The bear case therefore includes both a clinical setback and the possibility of clinical progress that does not translate into attractive economics per existing share. Source Source

What Would Falsify This Reading

The central reading is that pediatric commercialization is advancing, while financing and adult efficacy remain unresolved determinants of shareholder outcomes.

• Repeat use fails to follow access. If new hospitals and the effective October codes do not translate into recurring orders, the commercial opportunity would be weaker than customer additions alone suggest. The August update reported 20 customers, not a recurring revenue guarantee. Source Source
• The adult completion window moves materially. A significant delay beyond the year-end 2026 or Q1 2027 enrollment target would weaken the timetable supporting a possible late-2027 PMA submission and extend the period requiring finance. Those remain company targets, conditional on progress and results. Source
• The safety or efficacy picture deteriorates. A new material safety signal or an unconvincing adult treatment effect would challenge the clinical reading. The September FDA review supports pediatric safety in its defined period, rather than guaranteeing future adult success. Source Source
• Funding becomes more favorable than the cash picture implies. A substantial financing with limited economic dilution, or sustained sales that materially reduce cash use, would weaken the present emphasis on funding pressure. Capacity alone does not demonstrate that improvement. Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 What SeaStar sells and what still needs approval

SeaStar Medical sells QUELIMMUNE, its pediatric Selective Cytopheretic Device, and is developing an adult version through NEUTRALIZE-AKI. The distinction is central to the company. The pediatric product received FDA Humanitarian Device Exemption approval on February 21, 2024; the adult programme remains a development programme. The approved pediatric indication covers patients weighing at least 10 kilograms and aged 22 years or younger with acute kidney injury caused by sepsis or a septic condition, on antibiotics and requiring renal replacement therapy. Source Source

The device connects to an existing continuous kidney replacement circuit and is designed to modify the activity of overactivated inflammatory cells. Its investment relevance is the possibility of improving organ recovery without requiring a hospital to build an entirely separate treatment infrastructure. Whether that possibility produces sustained commercial use depends on evidence, hospital adoption and the economics of delivering treatment. It cannot be inferred from the mechanism alone. Source

The HDE pathway matters because pediatric authorization is based on safety and probable benefit in a rare condition. It is not proof that the device has already demonstrated an adult survival benefit in a large successful pivotal trial. The FDA safety memo prepared for the September 16, 2026 Pediatric Advisory Committee meeting concluded that the HDE remains appropriate for its pediatric population. That supports the existing commercial indication while leaving the adult evidence requirement intact. Source

The company reports six FDA Breakthrough Device Designations for the SCD therapy, covering adult AKI, cardiorenal syndrome in patients awaiting a left ventricular assist device, hepatorenal syndrome, end-stage renal disease and the systemic inflammatory response in adult and pediatric patients undergoing cardiac surgery. Among SeaStar-sponsored studies on ClinicalTrials.gov, the only active one outside AKI is a feasibility study in cardiorenal patients awaiting an LVAD, listed on ClinicalTrials.gov as recruiting with an estimated 20 participants (NCT03836482). Those designations can facilitate regulatory interactions, but expanding into additional diseases would require development expenditure and the appropriate approvals. For shareholders, the immediate economic business is QUELIMMUNE sales; the larger adult opportunity remains conditional. Giving all potential indications the same weight as an approved product would obscure both the funding requirements and the different probabilities of reaching the market. Source

The adult pathway gained a designation on October 7, 2026. The FDA granted Breakthrough Device Designation to the SCD therapy for hyperinflammation in adults with sepsis or a septic condition, the seventh for the platform after designations in adult AKI, adult and pediatric cardiac surgery, cardiorenal syndrome, end-stage renal disease and hepatorenal syndrome. Breakthrough status offers more interaction with the FDA and prioritized review, but it neither approves the device for adults nor shortens the evidence needed: for sepsis the relevant data will come from the pre-specified subgroups of NEUTRALIZE-AKI. Company release

03 The October codes: useful infrastructure, not guaranteed payment

SeaStar’s October 1, 2026 announcement confirms that dedicated ICD-10-PCS codes are now available for its SCD therapy in the inpatient setting. The three codes are 5A1D701 for intermittent treatment of less than six hours, 5A1D801 for prolonged intermittent treatment of six to eighteen hours and 5A1D901 for continuous treatment of more than eighteen hours, each described as urinary filtration by selective cytopheresis. SeaStar first announced the codes on June 23, 2026; they became usable on October 1, the start of the new coding year. The release names no payment amount. Their practical purpose is to let hospitals identify and document the procedure consistently in administrative, billing and statistical systems. For a young hospital product, removing ambiguity in those systems can be commercially helpful. Source

The distinction for a trader is between a usable code and a payment outcome. A procedure code identifies what was done; it does not by itself establish a new guaranteed reimbursement amount, compel every payer to cover the treatment or guarantee that an individual claim will be paid. The announcement describes a standardized route for reporting treatment. The evidence of commercial benefit would come later through ordering, repeat demand and the financial results of the product. Source

The codes can also provide infrastructure for an adult commercial market if the adult device gains approval. That future applicability does not authorize adult commercialization in advance. A headline connecting the codes to the adult market needs that condition attached; otherwise an administrative improvement can be mistaken for a regulatory decision. Source

For operating performance, the useful question is whether the coding change reduces friction at hospitals that are already considering the product. More efficient billing could support adoption, but it would work alongside clinical education, local review and the availability of eligible patients. Hospitals do not become customers simply because a code exists, and a first order does not establish recurring demand. Subsequent company updates need to connect these practical steps to revenue rather than leave the code as a standalone promotional milestone.

04 QUELIMMUNE sales: growth from a small starting point

For the quarter ended June 30, 2026, SeaStar reported revenue of $615,000, compared with $338,000 a year earlier, an increase of approximately 82%. First-half revenue was $1.110 million, versus $631,000 in the first half of 2025. Subtracting the second quarter from the first-half total gives first-quarter 2026 revenue of $495,000; the second quarter was therefore approximately 24.2% higher sequentially, calculated from the reported accounts. These are product sales, not a financing receipt. Source

The August 12 business update reported three new hospital customers during the second quarter, bringing the customer base to 20, together with deeper ordering by existing customers. That distinction between new accounts and repeat business is useful. New hospital adoption establishes access to another clinical team; repeat orders provide better evidence that the product is becoming part of ordinary treatment decisions at an established account. Source

SeaStar remains small enough that the timing of treatment cases and hospital orders can move quarterly revenue considerably. A strong percentage increase should therefore be read with the dollar base beside it. The June quarter’s $615,000 of sales does not establish a predictable sales rate across all enrolled hospitals, nor does dividing it by the customer count produce a reliable recurring revenue figure per hospital. The company itself warns that product revenue can fluctuate as commercialization develops. Source

The 10-Q also puts the commercial history in perspective: since launch, QUELIMMUNE has generated approximately $2.5 million of revenue in total. Against a first-half 2026 net loss of $7.251 million, that cumulative figure shows how far the pediatric business still is from carrying the company, whatever the recent growth rate. Source

The next commercial update should be judged on the quality of growth: whether established hospitals reorder, whether newly added hospitals begin using the device, and whether greater adoption is accompanied by improved cash collection. A growing customer list with little corresponding revenue would be less persuasive than broader repeat use. The coding change creates a reason to watch those measures closely, but it does not pre-answer the result. Source Source

05 Margins and expenditure: why sales growth has not removed the funding need

SeaStar’s June-quarter gross profit was $561,000 on $615,000 of sales, equivalent to a calculated gross margin of approximately 91.2%. That is a high product-level margin. The same quarter, however, included $2.520 million in research and development expense and $1.832 million in general and administrative expense, producing an operating loss of $3.791 million. The gross margin is not an operating margin or a cash-flow margin. Source

The clinical programme is a major reason for that gap. Second-quarter clinical-trial expense was $1.257 million, compared with $633,000 a year earlier. Research and development also includes clinical and medical personnel and external development services. Successful enrollment can therefore increase near-term expenditure before it creates any revenue from the adult indication. A faster trial is commercially valuable only if SeaStar can pay for the work and reach a useful result. Source

Year-on-year expense comparisons also contain compensation effects. The company explains that the prior-year quarter benefited from rescinded unpaid bonuses and director fees, while current-period legal and other costs increased. The rise in expenses should not all be described as a direct measure of more patients treated. Conversely, the presence of such comparative effects does not make the current cash requirement disappear. Source

Part of the general and administrative increase came from about $0.4 million of additional legal expense tied to litigation, which ended during the same quarter. In the securities class action filed in July 2024 over the 2024 restatement, the District of Colorado dismissed the complaint with leave to amend on March 30, 2026; the parties then stipulated to a dismissal with prejudice, ordered on April 27, 2026. The related derivative action was dismissed without prejudice by stipulation on May 12, 2026. A dismissal without prejudice can in principle be refiled, so the 10-Q disclosure remains worth checking in the next quarterly report. Source

The practical test is whether gross profit begins to cover a larger share of the recurring expense base while the adult trial advances. At this stage, commercial growth and financing have to work together. Treating the product’s gross margin as evidence that the company is close to self-funding would skip the cost of the very programme that could expand its future market.

06 Pediatric clinical evidence: promising observations with important limits

The 2024 Kidney Medicine publication pooled 22 children treated with SCD plus kidney replacement therapy. Seventeen survived to intensive-care discharge or day 60, approximately 77%. The historical-comparator analysis reported an adjusted survival odds ratio of 2.65 with a confidence interval of 0.93–7.53 and p=0.07; that overall comparison did not meet the conventional 0.05 threshold. When patients also receiving ECMO were excluded, the adjusted odds ratio rose to 13.4 (1.7–103; p=0.01), a subgroup result with a very wide interval. The study was small and used a historical comparator. These results support probable benefit, but do not justify describing a precisely measured causal reduction in mortality. Source

This is where the company’s own wording and the publication are best read side by side. SeaStar’s August release describes the Kidney Medicine data as a 77% survival rate representing “an approximate 50% reduction in loss of life compared to historical data.” The study authors’ adjusted comparison for all patients, by contrast, was not statistically significant. Both statements rest on the same small dataset; the first is a promotional reading of a historical comparison, the second is the statistical test of it. Source Source

The early post-approval report from the SAVE registry, published in Pediatric Nephrology in 2026, described the first 21 patients. Sixteen of 21 survived through day 60 and 15 of 21 through day 90, approximately 76% and 71%. Three positive blood cultures occurred during follow-up and were considered unrelated to the device; no device-related adverse events were reported, and three patients died while still on therapy. These are descriptive observations, not a randomized efficacy comparison, and the publication does not supply an efficacy p-value for those survival proportions. Source

A larger set of registry patients has since been presented by the company, but not published. At the AKI & CRRT 2026 meeting in March, SeaStar reported preliminary survival of 69% at day 28 and day 60 from eighteen months of post-approval experience, with no device-related adverse events; the release did not state how many patients the figure covers. The same pediatric registry is the subject of the October 22 ASN poster. Source Source

The FDA safety memo prepared for the September 16 Pediatric Advisory Committee meeting adds a more current regulatory perspective. Covering July 1, 2025 to June 30, 2026, it found no new safety signals, no adverse-event reports in the FDA’s MAUDE database and no safety-related label changes, and concluded that the pediatric HDE remains appropriate. It also records that the sponsor’s July 19 correspondence described 65 enrolled patients and that a preliminary report covering 50 patients had been received on June 1. The early publication’s 21-patient results are not the outcomes of all 65 patients. Source

The same memo records a detail that matters for the commercial reading. The original approval condition required a 300-patient surveillance registry within two years; in November 2025 the FDA approved a protocol change cutting the target to 50 patients, citing the device’s low utilization in clinical settings, the low number of exposed patients and the fact that all patients receive antibiotics. The memo also shows the sponsor planning a final registry report for August 2026, and it redacts the number of devices distributed as confidential commercial information. Source NCT06517810

For the investment case, these sources support continued pediatric use and the value of collecting broader experience. They do not make the adult trial redundant. Different populations, different comparisons and different reporting dates each matter separately when judging how much clinical uncertainty has actually been reduced.

07 NEUTRALIZE-AKI: the material clinical milestone

The August 12, 2026 update placed adult enrollment at 223 patients out of a planned 339. The company expected completion around year-end 2026 or into the first quarter of 2027. This is a company target window, not a fixed result date or an FDA decision deadline. Enrollment completion must be followed by the relevant outcome follow-up and analysis before a regulatory submission can rely on the results. Source

The central clinical question is whether adding SCD to standard care improves the combined outcome of death or dialysis dependence at 90 days in adults with acute kidney injury. The result must show a persuasive benefit against the control group with an acceptable safety profile. Enrollment counts show progress toward answering that question; they are not an early efficacy result. A target being reiterated does not itself reveal the eventual treatment effect. Source

The secondary endpoints listed by the company are mortality at day 28, ICU-free days within the first 28 days, major adverse kidney events at day 90 and dialysis dependency at one year, with planned subgroup analyses in patients with sepsis and acute respiratory distress syndrome. On ClinicalTrials.gov the trial (NCT05758077) started on April 17, 2023 and, in the record last updated on September 10, 2026, shows an estimated primary completion date of December 2026 and study completion in June 2027. Those registry dates are estimates and do not sit neatly with a 90-day primary endpoint and an enrollment window running into early 2027; the company’s own statements are the better guide to timing. Source

There is a reason to retain that distinction. The earlier adult randomized study published in 2015 enrolled 134 patients and did not show a significant difference in 60-day mortality in its overall intention-to-treat analysis: 39% (27 of 69) in the SCD group against 36% (21 of 59) among controls, p=0.23. In the subgroup that kept ionized calcium at or below 0.4 mmol/L for at least 90% of treatment time, mortality or dialysis dependency was 16% against 58% (p<0.01). ClinicalTrials.gov lists that study as terminated (NCT01400893). A favorable composite outcome in a selected subgroup with tightly maintained calcium conditions was hypothesis-supporting evidence, not an overall positive primary result. The ongoing programme needs to establish its own outcome rather than inherit success from that subgroup. Source

SeaStar’s August announcement linked a potential PMA application near the end of 2027 to a positive trial outcome. That schedule places financing between the current commercial business and the proposed adult submission. The next useful enrollment update would make clear whether the completion window still fits the observed recruitment progress. The later results would then need to disclose the effect size, patient numbers, statistical support and safety outcomes that determine whether the adult thesis holds. Source

08 Cash and monthly burn: the dates matter

Cash was $6.959 million at June 30, 2026, down from $11.980 million at December 31, 2025. Operating activities used $5.755 million over the first six months of 2026. Dividing that operating use by six gives a calculated historical burn of approximately $959,000 per month. This is a first-half average, not the cash consumption of a particular later month. Source

Dividing June cash by that average produces approximately 7.3 months of static coverage measured from June 30. The calculation assumes an unchanged spending rate and excludes later financing and operational changes. Taken literally, the arithmetic would reach early February 2027 before counting the roughly $0.4 million raised after June 30, a Merlintrader calculation rather than a forecast. It is not a company runway promise, an October cash balance or a predicted date of insolvency. Clinical expenditure, order timing, collections and equity proceeds can all change the actual path. Source

The company’s own assessment is more important than that simple ratio: the August financial report says the company does not believe its cash on hand will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, for at least twelve months from the issuance of the statements, and that these conditions raise substantial doubt about its ability to continue as a going concern. This is a funding risk attached to the business plan, not a statement that the company had already ceased operating. It means future capital is an essential input to completing that plan. Source

Operating cash flow also benefited from a $1.200 million increase in accrued expenses during the first half. Accruing an expense delays the cash payment rather than eliminating the obligation. A trader should therefore compare the next cash-flow statement with changes in unpaid liabilities, especially if the reported burn seems to improve while clinical activity expands. The quality of a lower burn rate depends on what caused it. Source

Stockholders’ equity is the other balance-sheet number to watch. It fell from $10.416 million at December 31, 2025 to $4.296 million at June 30, 2026. Nasdaq’s continued-listing standard under Rule 5550(b)(1) uses a $2.5 million equity threshold, and SeaStar had been under a mandatory panel monitor on exactly that requirement from July 1, 2025 until July 1, 2026, when it exited the monitor after maintaining compliance. Merlintrader calculation: the cushion above that threshold at June 30 was about $1.8 million, equal to roughly one and a half months of the first-half net loss rate ($7.251 million over six months), which points to around mid-August 2026 before counting new share issuance such as the roughly $0.4 million raised after June 30; even with that issuance and non-cash items, the arithmetic reaches the threshold by about September. The alternative market-value standard of the same rule, $35 million of listed securities, is also above the roughly $20.7 million value at the October 2 close (calculation). No deficiency notice has been disclosed through October 5, 2026; the third-quarter 10-Q will show where equity actually stands, and further equity issuance looks structurally likely (Merlintrader inference); the October 5 warrant inducement, which issues 854,002 shares and new warrants for 1,708,004 more, is one such step (chapter 10). Source Nasdaq Rule 5550

09 Financing capacity, ATM restrictions and the small debt balance

At June 30, 2026, SeaStar reported approximately $13.8 million of remaining capacity under its standby equity purchase agreement with Lincoln Park. The agreement provides a route for selling common shares over its contractual term, subject to conditions. The residual capacity is not cash already held, and using it increases the share count. Purchase prices are market-linked and purchases are also subject to contractual trading and ownership constraints. The agreement, signed on April 25, 2025, covers up to $15.0 million over 36 months from May 14, 2025; each purchase is priced at 97% of the lower of the day’s lowest sale price or the average of the three lowest closing prices in the previous ten trading days, and no sale may take Lincoln Park above 9.99% of the outstanding shares. Source

The company reported raising approximately $0.4 million through the issuance of 135,339 shares after July 1 in the subsequent-events section of the August report. That is evidence of actual use of the facility. It is not the same as drawing all of the residual capacity, nor can it simply be added to June cash and called the current balance without subtracting later spending. The amount and date of new funding both matter. Source

The shelf registration had approximately $55.9 million of nominal remaining capacity at June 30, after about $44.1 million had been raised. However, the company states that primary offerings were limited by baby-shelf restrictions and that it was restricted from raising capital through the ATM at that date. The nominal shelf balance therefore substantially overstates what can be treated as immediately available financing. The ATM history confirms the point: it has raised about $10.4 million net since August 2024, but only about $0.1 million (18,880 shares) in the first half of 2026. Source

Debt was modest compared with the development requirement: the June balance sheet carried $134,000 of insurance financing, with contractual payments scheduled through August 2026. That is a dated obligation, not evidence of its subsequent repayment. The main financial pressure is operating funding and potential equity dilution rather than a large long-term borrowing maturity. A small debt balance does not offset insufficient cash to execute the clinical plan. Source

10 Shares, warrants and the difference between possible and actual dilution

Common shares outstanding rose from 3,844,613 at December 31, 2025 to 4,259,842 at June 30, 2026 and 4,406,841 at August 5. The increase between the first and last dates was approximately 14.6%, calculated from the reported counts. All of these counts already reflect the 1-for-10 reverse stock split of January 5, 2026, which followed a 1-for-25 split in June 2024. These are issued shares; they differ from the weighted-average shares used to calculate quarterly earnings per share and from shares that might be issued under outstanding instruments. Source

At June 30, warrants represented 2,699,924 potential common shares. The large recent tranches were 994,616 shares at $6.57, 560,944 at $6.59 and 530,779 at $7.85, followed by 377,648 at $17.34; older instruments had much higher split-adjusted exercise prices. The Nasdaq close on October 2, 2026 was $4.69. Warrants that are out of the money are not a dependable source of near-term cash, even though they remain potential dilution if their terms and market conditions allow exercise. Source Source

The June accounts also reported 158,894 unvested restricted stock units and 1,764 employee options. They disclosed 425 million authorized common shares, a legal capacity that is much larger than issued capital. Authorized shares are not all outstanding, and their existence does not mean all will be issued, but it leaves room for financing and compensation transactions subject to the applicable requirements. Source

The amended incentive plan approved at the June 17 annual meeting raised the share reserve from 207,046 to 896,546 shares, an increase of 689,500 shares equal to about 15.6% of the August 5 share count (calculation); it passed with 551,233 votes for and 223,813 against, and the shares were registered on Form S-8 on July 21. Source Source The plan uses a specified share reserve and award rules. It is neither cash available to finance operations nor a forecast that every award will vest. For existing holders, actual share issuance, new financing terms and any repricing or modification of outstanding instruments are the economically meaningful developments. A headline about funding needs to be evaluated together with the securities issued in exchange. Source Source

Compensation arrangements add a small, dated layer. On June 25, 2026 the board’s compensation committee approved retention bonuses of $200,000 for chief executive Eric Schlorff and $140,000 for chief medical officer Kevin Chung (agreements signed June 29), payable in thirds on July 1, 2026, November 1, 2026 and March 1, 2027, with an extra 25% of each payment delivered in shares; the July 1 restricted stock units reported on Forms 4 (10,288 for Schlorff, 7,202 for Chung) vest on the same three dates, while four directors each received 4,000 units vesting on July 1, 2027. Cash payments of this size are modest against quarterly operating costs, but they are a commitment the company has made while warning about going concern. Source Source Source

An October 5, 2026 transaction turns part of that potential dilution into actual dilution. SeaStar announced that holders had agreed to exercise existing warrants for 854,002 common shares at a reduced exercise price of $3.866, for gross proceeds of approximately $3.3 million before placement-agent fees; H.C. Wainwright acted as placement agent, the agreements were signed on October 2 and closing was expected on or about October 5. In exchange, the company will issue new unregistered warrants for up to 1,708,004 shares at $3.616, exercisable immediately, in two equal tranches of 854,002 that expire five years and eighteen months, respectively, after the resale registration becomes effective; SeaStar agreed to file that registration within 30 days of October 2. Source The release identifies the exercised warrants as instruments issued in June, July and August 2025 with exercise prices between $6.38 and $7.62; those prices do not match one for one the tranches summarized above from the June 30 table, so the third-quarter 10-Q is where the remaining warrant count should be confirmed. On the August 5 base of 4,406,841 shares, the 854,002 new shares equal about 19.4%, and the new warrants about 38.8% (calculations). The exercise price is about 17.6% below the $4.69 close of October 2 (calculation). Proceeds are for general corporate purposes. The cash extends the runway discussed in chapter 08 at a cost in dilution, and it replaces higher-priced warrants with a larger number at a lower price.

The transaction closed on October 5, 2026, according to a Form 8-K filed the same day: gross proceeds were approximately $3.3 million before placement agent fees and offering expenses, and the new investor warrants comprise Series A and Series B warrants, each for 854,002 shares at $3.616, immediately exercisable, with terms of five years and eighteen months respectively from the effective date of the resale registration statement. The filing adds a further dilution item not covered above: H.C. Wainwright & Co., the placement agent, receives warrants for 59,780 shares at $4.8325, immediately exercisable, with a term of five years from the effective date of the resale registration statement. Source Together the new warrants cover 1,767,784 shares (calculation), which become shares only if exercised.

11 Ownership, insider activity and the dated short position

Nasdaq reported short interest of 121,686 shares at the September 15, 2026 settlement date, equal to 2.73 days of average volume. Measured against the 4,406,841 shares outstanding on August 5, that is about 2.8%, a Merlintrader calculation. The earlier settlements were 91,177 shares (July 31), 121,687 (August 14) and 110,622 (August 31), so the position has been broadly stable and small. The December 2025 settlements of about one million shares predate the 1-for-10 reverse split of January 5, 2026 and are only comparable after dividing by ten. Short interest is published with a lag, so these figures do not describe positions after the October 2 session. Source

Market data show a float of about 4.27 million shares, a short ratio of 1.67, insider ownership of 3.10% and institutional ownership of 3.86% (Finviz, as of October 2, 2026). These are unverified third-party figures; the 2.85% short-of-float figure on the same page appears to be the September 15 Nasdaq number divided by that float (Merlintrader calculation). Source

A small float can make the share price sensitive to changing demand, but it does not establish a short squeeze. The short ratio depends on the trading-volume basis used to calculate it and does not mean shorts must cover within that number of days. The more useful combination is the available float, the amount of short exposure and the potential arrival of new shares through financing. These figures describe trading structure, not a clinical or regulatory outcome.

One disclosed large beneficial owner requires particular care. Intracoastal’s May 13 filing reported 443,253 beneficial shares, or 9.99%, as of March 31, with that position arising from exercisable warrant shares and ownership blockers. It is not a statement that Intracoastal held that many already-issued common shares purchased on the market, and its dated regulatory percentage is not additive to the October market-data percentages. Without the blockers, the filing says the position would have been 534,285 shares. Source

A second warrant holder filed in the same week. Ayrton Capital, investment manager of Alto Opportunity Master Fund, reported on May 11, 2026 beneficial ownership of 278,436 shares, or 6.52%, as of March 31, consisting entirely of shares issuable on exercise of warrants subject to a 9.99% blocker. Together with Intracoastal, these filings show that a meaningful part of the potential dilution sits with financial investors whose warrants are, at current prices, out of the money. Source

The CFO’s August 19 filing reports a genuine purchase: Michael Messinger acquired 750 common shares at $3.27 on August 18, taking his reported direct holding to 2,500 shares. By contrast, the CEO’s July 1 transaction was an award of 10,288 restricted stock units, vesting in thirds on July 1 and November 1, 2026 and March 1, 2027, rather than an open-market purchase; his reported holding after the award was 50,140 shares. No Form 4 has been filed since August 19. The purchase is a positive alignment signal of modest size; neither it nor an award establishes a company funding solution or predicts clinical success. Source Source

12 The next events and how to judge them

The nearest announced appearance is the PPETS meeting in Houston on October 6–8, 2026. SeaStar’s September 29 announcement places the relevant morning session on October 6. This is a clinical education and device-development appearance, not an announced pivotal data release. Its immediate relevance is communication with clinicians, while material new data would need its own identifiable result and source. Source

The next dated item with clinical content is ASN Kidney Week in Denver. The poster “Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort” (TH-PO1291) is scheduled for October 22, 2026, 10:00 a.m. to noon MT. Its authors include Stuart Goldstein and SeaStar’s Kevin Chung. It concerns the approved pediatric use and compares registry patients with a historical cohort, so any survival difference it reports would carry the same comparator limits discussed in the pediatric evidence chapter. Source

The third-quarter report has no announced date. For reference only, the 2025 third-quarter 10-Q was filed on November 13, 2025. The second retention-bonus and RSU vesting date, November 1, 2026, falls just before that window. EDGAR Source

The larger operating checkpoints are the next quarterly financial report, further hospital adoption and the next adult enrollment update. A financial release should connect cash use, new shares issued and sales growth. An enrollment release should specify the number reached and whether the year-end 2026/first-quarter 2027 completion target remains realistic. Neither type of update should be judged solely by the headline percentage increase or by a reiterated expression of confidence. Source Source

For the eventual adult result, the decisive information would include the main clinical outcome, the treatment and control populations, statistical support and safety. A subgroup benefit would need to be identified as such. For funding, the decisive information would be net proceeds, securities issued, exercise or conversion terms where relevant, and how far the financing extends the development plan. Those are separate questions even when both announcements arrive close together.

The existing pediatric authorization, the effective billing codes and the SAVE registry enrollment minimum, reached after the FDA lowered it from 300 to 50 patients, are milestones already reached. The adult trial result and a possible subsequent PMA application remain future conditional steps. Keeping that separation prevents past achievements from being presented as upcoming catalysts and avoids treating a future target as a commitment from the regulator. Source Source Source

13 Red flags and the bottom line

The first red flag is a mismatch between the cash available and the time needed to establish the adult opportunity. June cash, first-half operating use and the going-concern disclosure show why another funding step matters. Revenue growth is helpful, but the commercial base has not yet removed the need to raise capital. A financing that keeps development moving may still be costly to existing shareholders. Source

A second red flag would be overinterpreting supportive evidence. Pediatric survival observations, a reassuring safety review, procedure codes and breakthrough designations each answer different questions. None means that NEUTRALIZE-AKI has succeeded. The earlier adult trial’s overall result is another reason to require direct evidence from the current programme instead of extrapolating from selected favorable comparisons. Source Source Source

The constructive elements are tangible: an approved pediatric product, reported hospital customers, increasing product revenue, and more standardized hospital coding. The constraint is equally tangible: a small cash balance relative to development expenditure and financing routes that can dilute shareholders. The Nasdaq close of $4.69 on October 2, 2026, about $20.7 million of market value on the August 5 share count (calculation), supplies a dated market context, not a valuation verdict or an investment recommendation. Source Source Source Source

SeaStar’s next stage will be judged by the interaction of those facts. Stronger repeat hospital use would support the commercial thesis. Funded adult enrollment and a convincing result would support the larger clinical opportunity. Better outcomes for the company would reach existing shareholders only to the extent that the capital required to get there leaves them with a meaningful economic interest. That is the central distinction to carry into the next operating, financing and clinical announcements.